SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

10 Feb 2022 Evaluate
The quarter ended December 2021 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 4395.59 millions.The Net Loss for the quarter ended December 2021 is Rs. -176.03 millions as compared to Net Profit of Rs. 204.89 millions of corresponding quarter ended December 2020Operating profit for the quarter ended December 2021 decreased to 111.42 millions as compared to 696.49 millions of corresponding quarter ended December 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 4395.59 4210.85 4.39 15233.46 12239.67 24.46 18575.66 16919.32 9.79
Other Income 92.21 261.90 -64.79 433.17 950.20 -54.41 1170.85 930.71 25.80
PBIDT 111.42 696.49 -84.00 974.52 1649.88 -40.93 2763.16 2975.28 -7.13
Interest 166.00 171.32 -3.11 526.94 474.32 11.09 653.39 668.43 -2.25
PBDT -54.58 525.17 -110.39 447.58 1175.56 -61.93 2109.77 2306.85 -8.54
Depreciation 262.32 251.53 4.29 799.57 746.15 7.16 993.42 942.40 5.41
PBT -316.90 273.64 -215.81 -351.99 429.41 -181.97 1116.35 1364.45 -18.18
TAX -140.87 68.75 -304.90 -148.83 127.75 -216.50 333.95 161.70 106.52
Deferred Tax -140.87 37.88 -471.88 -148.83 52.39 -384.08 123.77 9.70 1175.98
PAT -176.03 204.89 -185.91 -203.16 301.66 -167.35 782.40 1202.75 -34.95
Equity 897.90 896.35 0.17 897.90 896.35 0.17 896.80 895.70 0.12
PBIDTM(%) 2.53 16.54 -84.68 6.40 13.48 -52.54 14.88 17.59 -15.41

Strides Pharma Scien Share Price

1007.50 6.80 (0.68%)
20-Apr-2026 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.00
Dr. Reddys Lab 1234.90
Cipla 1239.00
Zydus Lifesciences 947.70
Lupin 2332.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×